CYTOMX THERAPEUTICS INC (CTMX) Stock Income Statement
NASDAQ:CTMX - Nasdaq - US23284F1057 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 138.10M | 101.21M | 53.20M | 37.30M | 100.40M | |||
| Operating Expenses | 113.11M | 107.70M | 146.80M | 153.40M | 149.00M | |||
| Research and Development | 83.38M | 77.68M | 106.30M | 114.20M | 112.90M | |||
| Selling, General, and Administrative Expenses | 29.73M | 30.02M | 40.40M | 39.20M | 36.00M | |||
| Operating Income | 25.00M | -6.48M | -93.60M | -116.00M | -48.60M | |||
| Interest Income/Expense | 7.14M | 9.84M | 1.70M | 300.00K | 1.80M | |||
| Other Income/Expense | -38.00K | -30.00K | 300.00K | -100.00K | 0.00 | |||
| Non Recurring Items | N/A | N/A | -7.70M | N/A | N/A | |||
| Income Before Taxes | 32.09M | 3.32M | -99.30M | -115.90M | -46.80M | |||
| Income Tax | 224.00K | 3.89M | 0.00 | 0.00 | -13.90M | |||
| Net Income | 31.87M | -569.00K | -99.30M | -115.90M | -32.90M | |||
| EBITDA | 26.76M | -4.31M | -91.20M | -113.30M | -46.10M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.38 | -0.01 | -1.51 | -1.81 | -0.71 | |||
| Non GAAP EPS | 0.39 | -0.02 | -1.52 | -1.31 | -0.72 | |||
| Statistics | ||||||||
| Profit Margin | 23.08% | -0.56% | -186.65% | -310.72% | -32.77% | |||
| Operating Profit Margin | 18.10% | -6.41% | -175.94% | -310.99% | -48.41% | |||
All data in USD